A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Tetanus-diphtheria-acellular Pertussis (Tdap)

Interventions

BIOLOGICAL

GC3111B

0.5 mL, Intramuscular injection

BIOLOGICAL

Boostrix®

0.5 mL, Intramuscular injection

Trial Locations (1)

RECRUITING

The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul